Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
Date:2/19/2009

on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
2. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
3. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
4. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
5. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
6. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
7. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
8. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
9. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
10. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Portal Solutions , a technology consulting firm ... Office 365 and SharePoint platforms , today announces its inclusion ... one of the region’s fastest-growing mid-sized companies based on a ... “To be recognized a second year in a row by ...
(Date:1/22/2015)... Md. (PRWEB) January 22, 2015 ... its new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength ... high-quality instrument is ideal for applications in a ... life science. , The user-friendly UV-1280 enables intuitive ...
(Date:1/22/2015)... NH (PRWEB) January 22, 2015 GEA ... a table top laboratory homogenizer, the PandaPLUS 2000, which ... nanodispersions, nanoemulsions , and cell disruption . This ... dairy products, fruit juices, liquid food, food additives and ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Cambridge Semantics Announces Record Results for 2014 2
... , , , ... MTA: CTIC) today reported recent achievements and financial results for the ... , "The second quarter of 2009 was a transforming ... setting, pixantrone phase III data at the American Society of Clinical ...
... clean energy source, some engineers want to pack hydrogen into ... tank. A gas flows easily out of a tank, but ... researchers reveal new details about one such catalyst. The results ... energy applications such as fuel cells. Scientists from the ...
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing novel ... Drug Administration (FDA) has extended the Prescription Drug User Fee Act ... review the new drug application (NDA) for Qutenza(TM) to manage pain ...
Cached Biology Technology:Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 2Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 3Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 4Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 5Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 6Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 7New clues about a hydrogen fuel catalyst 2New clues about a hydrogen fuel catalyst 3NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application 2NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application 3NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application 4
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... make it easier to detect and prevent counterfeit microcircuits ... the agency started performing an in-house microcircuit anti-counterfeit initiative ... of purchased microcircuits while increasing their reliability throughout the ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... the western Pacific Ocean caused by an unprecedented strengthening of ... the hiatus in surface warming observed over the past 13 ... Nature Climate Change indicates that the dramatic acceleration in ... more heat to be taken out of the atmosphere and ...
... as important on, and especially off, Earth as breathable, quality ... seconds to spare, which is why development of the Multi-Gas ... measure the concentrations of multiple gases within the air inside ... Multi-Gas Monitor to be resistant to shock and vibration so ...
... case that one well-known type of cholesterol is a likely ... on the causal role played by another type. The findings ... Most of us have heard of "good cholesterol" and ... wisdom of the past 30 years, having more of the ...
Cached Biology News:Pacific trade winds stall global surface warming -- for now 2Rugged, rapid monitor safeguards space crews 2Rugged, rapid monitor safeguards space crews 3Researchers use genetic signals affecting lipid levels to probe heart disease risk 2Researchers use genetic signals affecting lipid levels to probe heart disease risk 3
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
... Polyclonal IgY Antibodies Hypothetical protein FLJ20644, ... g4-1 Protein Accession #: NP_060387.1 ... Genbank Definition: chromosome 14 ... mouse phosphatase subunit gene g4-1 [Homo sapiens] ...
Myt 1 (N-17)...
HSV-1 gE Envelope Protein (9H3)...
Biology Products: